Acute electronic cigarette use: nicotine delivery and subjective effects in regular users.

Drugs and Addictive Behaviours Research Group, School of Psychology, University of East London, Water Lane, Stratford, London, E15 4LZ, UK, .
Psychopharmacology (Impact Factor: 3.99). 01/2014; 231(2):401-407. DOI: 10.1007/s00213-013-3249-8
Source: PubMed

ABSTRACT Electronic cigarettes are becoming increasingly popular among smokers worldwide. Commonly reported reasons for use include the following: to quit smoking, to avoid relapse, to reduce urge to smoke, or as a perceived lower-risk alternative to smoking. Few studies, however, have explored whether electronic cigarettes (e-cigarettes) deliver measurable levels of nicotine to the blood.
This study aims to explore in experienced users the effect of using an 18-mg/ml nicotine first-generation e-cigarette on blood nicotine, tobacco withdrawal symptoms, and urge to smoke.
Fourteen regular e-cigarette users (three females), who are abstinent from smoking and e-cigarette use for 12 h, each completed a 2.5 h testing session. Blood was sampled, and questionnaires were completed (tobacco-related withdrawal symptoms, urge to smoke, positive and negative subjective effects) at four stages: baseline, 10 puffs, 60 min of ad lib use and a 60-min rest period.
Complete sets of blood were obtained from seven participants. Plasma nicotine concentration rose significantly from a mean of 0.74 ng/ml at baseline to 6.77 ng/ml 10 min after 10 puffs, reaching a mean maximum of 13.91 ng/ml by the end of the ad lib puffing period. Tobacco-related withdrawal symptoms and urge to smoke were significantly reduced; direct positive effects were strongly endorsed, and there was very low reporting of adverse effects.
These findings demonstrate reliable blood nicotine delivery after the acute use of this brand/model of e-cigarette in a sample of regular users. Future studies might usefully quantify nicotine delivery in relation to inhalation technique and the relationship with successful smoking cessation/harm reduction.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We examined 1) changes in smoking and vaping behavior and associated cotinine levels and health status among regular smokers who were first-time e-cigarette purchasers and 2) attitudes, intentions, and restrictions regarding e-cigarettes. We conducted a pilot longitudinal study with assessments of the aforementioned factors and salivary cotinine at weeks 0, 4, and 8. Eligibility criteria included being ≥18 years old, smoking ≥25 of the last 30 days, smoking ≥5 cigarettes per day (cpd), smoking regularly ≥1 year, and not having started using e-cigarettes. Of 72 individuals screened, 40 consented, 36 completed the baseline survey, and 83.3% and 72.2% were retained at weeks 4 and 8, respectively. Participants reduced cigarette consumption from baseline to week 4 and 8 (p's < 0.001); 23.1% reported no cigarette use in the past month at week 8. There was no significant decrease in cotinine from baseline to week 4 or 8 (p's = ns). At week 8, the majority reported improved health (65.4%), reduced smoker's cough (57.7%), and improved sense of smell (53.8%) and taste (50.0%). The majority believed that e-cigarettes versus regular cigarettes have fewer health risks (97.2%) and that e-cigarettes have been shown to help smokers quit (80.6%) and reduce cigarette consumption (97.2%). In addition, the majority intended to use e-cigarettes as a complete replacement for regular cigarettes (69.4%) and reported no restriction on e-cigarette use in the home (63.9%) or car (80.6%). Future research is needed to document the long-term impact on smoking behavior and health among cigarette smokers who initiate use of e-cigarettes.
    Open Journal of Preventive Medicine 10/2014; 4(10):789-800. DOI:10.4236/ojpm.2014.410089
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To use a unique longitudinal data set to assess the association between e-cigarette use while smoking with smoking cessation attempts, cessation and substantial reduction, taking into account frequency of use and key potential confounders. Web-based survey, baseline November/December 2012, 1-year follow-up in December 2013. Great Britain. National general population sample of 4064 adult smokers, with 1759 (43%) followed-up. Main outcome measures were cessation attempt, cessation and substantial reduction (≥50% from baseline to follow-up) of cigarettes per day (CPD). In logistic regression models, cessation attempt in the last year (analysis n = 1473) and smoking status (n = 1656) at follow-up were regressed on to baseline e-cigarette use (none, non-daily, daily) while adjusting for baseline socio-demographics, dependence and nicotine replacement (NRT) use. Substantial reduction (n = 1042) was regressed on to follow-up e-cigarette use while adjusting for baseline socio-demographics and dependence and follow-up NRT use. Compared with non-use, daily e-cigarette use at baseline was associated with increased cessation attempts [odds ratio (OR) = 2.11, 95% confidence interval (CI) = 1.24-3.58, P = 0.006], but not with cessation at follow-up (OR = 0.62, 95% CI = 0.28-1.37, P = 0.24). Non-daily use was not associated with cessation attempts or cessation. Daily e-cigarette use at follow-up was associated with increased odds of substantial reduction (OR = 2.49, 95% CI = 1.14-5.45, P = 0.02), non-daily use was not. Daily use of e-cigarettes while smoking appears to be associated with subsequent increases in rates of attempting to stop smoking and reducing smoking, but not with smoking cessation. Non-daily use of e-cigarettes while smoking does not appear to be associated with cessation attempts, cessation or reduced smoking. © 2015 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
    Addiction 04/2015; DOI:10.1111/add.12917 · 4.60 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: An electronic cigarette or e-cigarette is a battery-powered vaporiser that simulates tobacco smoking by producing an aerosol that resembles smoke. It generally uses a heating element that vaporises a liquid solution known as e-liquid. Even though invented in China in 2004, it was introduced only recently to the market worldwide (Pauly et al. 2007; Henningfield and Zaatari 2010) as an alternative to tobacco cigarettes. Since then, e-cigarettes have achieved aworldwide popularity with increasing sales every year. E-liquids usually contain a mixture of propylene glycol, vegetable glycerol, and flavourings with or without nicotine. In contrast to tobacco smoking, the vapour of an e-cigarette is not the result of a combustion process and is believed to have much lower health effects. However, the risks of e-cigarette use are uncertain which is due to the limited amount of scientific data regarding their health effects related to the variability of vaporisers, e-liquid ingredients and their quality (Dawkins and Corcoran 2014; Farsalinos and Polosa 2014; Grana et al. 2014). Moreover, there are also limited amounts of studies looking on the in vitro toxicity profile of e-liquids and e-cigarettes by using cultured cells of the lung (Misra et al. 2014), mammalian fibroblasts (Romagna et al. 2013) and myocardial cells (Farsalinos et al. 2013). Prompted by this background, the present study was performed to compare the shortterm and long-term toxic effects of tobacco smoke with those vapour of various e-liquids from Happy People GmbH, 80337 Munich, Germany.